For more information, please see the full ClinicalTrials.gov posting NCT05771831.
Rockville, Md. (June 10, 2024) – Cellphire Therapeutics, Inc. (“Cellphire”), a clinical stage biotechnology company developing next-generation, allogeneic, platelet-derived, cellular therapeutics is happy to acknowledge the clinical research team at Rigshospitalet Copenhagen University Hospital, Denmark for completing enrollment of 41 patients in the study of Thrombosomes® (Freeze-dried platelet hemostatic, FPH) in Acute Aortic Dissections (NCT05771831). The Copenhagen team has done an incredible job under the leadership of Dr. Jakob Stensballe and Dr. Annette Ulrich in completing enrollment ahead of schedule. This study hopefully represents a significant step forward in the development of life saving cellular therapeutics.
“We look forward to the completion of ongoing data analysis, publication of the results, and potential future collaborations with the Rigshospitalet team”, said G. Michael Fitzpatrick, Chief Scientific Officer of Cellphire.
"We are very happy with the collaborative effort between Cellphire Therapeutics and Rigshospitalet, Copenhagen University Hospital, in advancing the study of FPH," remarked Dr. Jakob Stensballe, lead investigator of the study. "This milestone achievement reflects our shared commitment to innovation and patient care, and we eagerly anticipate the insights that will emerge from the data analysis."
Dr. Annette Ulrich, co-investigator of the study, states, "Completing enrollment ahead of schedule is a testament to the dedication and expertise of our research and clinical teams. We are optimistic about studying the potential impact of the FPH technology in improving outcomes for patients with Acute Aortic Dissection."
Completing patient enrollment marks a significant step forward in evaluating the FPH technology in a critical clinical setting. Cellphire Therapeutics looks forward to the potential continued collaboration with the esteemed team at Rigshospitalet, University of Copenhagen, and anticipates the dissemination of study results that may contribute to advancements in patient care worldwide.
The Thrombosomes® (FPH) used in this study were funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services, under contract number HHSO100201300021C.
About Cellphire Therapeutics:
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic, platelet derived, cellular therapeutics. Cellphire is applying its proprietary technologies to develop lifesaving products. With two hemostatic products in Phase 2 clinical development, Cellphire’ s technologies address significant unmet needs for hemostatic therapeutics. Across the range of geographies, clinical settings and indications. These include rural and 3rd world use, Orphan populations, perioperative use for surgery and trauma, and brain hemorrhage. For more information, visit Cellphire Therapeutics at www.Cellphire.com.
About Rigshospitalet, University of Copenhagen:
Rigshospitalet, University of Copenhagen, is a leading medical institution renowned for its commitment to excellence in patient care, education, and research. With a multidisciplinary approach and a focus on collaboration, Rigshospitalet is at the forefront of advancing medical knowledge and driving innovations in healthcare.
Contact Information:
Rob Woods
VP, Business Operations
RWoods@Cellphire.com